Literature DB >> 32139329

Acute superior mesenteric venous thrombosis results in high rates of readmission and morbidity.

Elizabeth Andraska1, Lindsey Haga1, Katherine Reitz1, Xiaoyi Li1, Rafael Ramos1, Efthymios Avgerinos1, Michael Singh1, Mohammad Eslami1, Michel Makaroun1, Rabih Chaer2.   

Abstract

OBJECTIVE: Superior mesenteric venous thrombosis (MVT) is a poorly understood clinical entity, and as such, outcomes are poorly described. This study aimed to identify predictors of bowel ischemia after MVT and to compare outcomes for patients treated medically (group 1) with those for patients treated with bowel resection (group 2).
METHODS: This was a retrospective, single-institution study capturing all patients diagnosed with symptomatic acute MVT on computed tomography imaging from 2008 to 2018. Demographics, comorbidities, imaging, laboratory values, and treatment were included. Predictors of bowel resection were analyzed by univariate and multivariate statistics. Outcomes including mortality, readmissions for abdominal pain, and chronic mesenteric venous congestion were compared using χ2 test.
RESULTS: There were 121 patients included in the study; 98 patients were treated medically (group 1), 19 patients were treated with bowel resection (group 2), and 4 patients were treated with endovascular recanalization (group 3). Group 1 and group 2 were compared directly. Patients requiring bowel resection tended to have higher body mass index (P = .051) and a hypercoagulable disorder (P = .003). Patients who required bowel resection were more likely to present with lactic acidosis (P < .001) and leukocytosis (P < .001) with bowel wall thickening on scan (P < .001). On multivariable analysis, a genetic thrombophilia was a strong predictor of bowel ischemia (odds ratio, 3.81; 95% confidence interval, 1.12-12.37). One-year mortality and readmission rates did not differ between groups. However, readmission rates for abdominal pain were high for both groups (group 1, 44.90%; group 2, 57.89%; P = .317), and a significant proportion of patients exhibited chronic mesenteric venous congestion on repeated scan (group 1, 42.86%; group 2, 47.37%; P = .104).
CONCLUSIONS: A genetic hypercoagulable disorder is a predictor of bowel ischemia due to MVT. Regardless of treatment, outcomes after MVT are morbid, with high rates of readmission for abdominal pain. An alternative approach to treat these patients is needed, given the poor outcomes with current strategies.
Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypercoagulable disorder; Mesenteric ischemia; Mesenteric venous thrombosis

Mesh:

Substances:

Year:  2020        PMID: 32139329      PMCID: PMC7434641          DOI: 10.1016/j.jvsv.2020.01.007

Source DB:  PubMed          Journal:  J Vasc Surg Venous Lymphat Disord


  25 in total

Review 1.  Mesenteric venous thrombosis.

Authors:  Cori E Russell; Rishi K Wadhera; Gregory Piazza
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

Review 2.  Mortality after acute primary mesenteric infarction: a systematic review and meta-analysis of observational studies.

Authors:  F Adaba; A Askari; J Dastur; A Patel; S M Gabe; C J Vaizey; O Faiz; J M D Nightingale; J Warusavitarne
Journal:  Colorectal Dis       Date:  2015-07       Impact factor: 3.788

3.  Portal, splenic and mesenteric vein thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation.

Authors:  Elisavet Grouzi; Marianna Politou; Panagiota Douramani; Efrosyni Merkouri; Argyri Gialeraki; Hlias Brountzos; Georgios Perros; Anthi Travlou
Journal:  Blood Coagul Fibrinolysis       Date:  2009-12       Impact factor: 1.276

4.  Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis.

Authors:  Michael Hollingshead; Charles T Burke; Matthew A Mauro; Susan M Weeks; Robert G Dixon; Paul F Jaques
Journal:  J Vasc Interv Radiol       Date:  2005-05       Impact factor: 3.464

5.  Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study.

Authors:  Stefan Acosta; Mats Ogren; Nils-Herman Sternby; David Bergqvist; Martin Björck
Journal:  J Vasc Surg       Date:  2005-01       Impact factor: 4.268

6.  Mesenteric vein thrombosis in a patient heterozygous for factor V Leiden and G20210A prothrombin genotypes.

Authors:  Paras Karmacharya; Madan Raj Aryal; Anthony Donato
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Mesenteric venous thrombosis.

Authors:  Ashwani K Singal; Patrick S Kamath; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2013-02-27       Impact factor: 7.616

8.  Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.

Authors:  Francesco Dentali; Walter Ageno; Dan Witt; Alessandra Malato; Nathan Clark; David Garcia; Kathleen McCool; Sergio Siragusa; Shannon Dyke; Mark Crowther
Journal:  Thromb Haemost       Date:  2009-09       Impact factor: 5.249

9.  Interventional Treatment of Acute Portal Vein Thrombosis.

Authors:  Karsten Wolter; Georges Decker; Daniel Kuetting; Jonel Trebicka; Steffen Manekeller; Carsten Meyer; Hans Schild; Daniel Thomas
Journal:  Rofo       Date:  2018-07-25

Review 10.  Splanchnic Vein Thrombosis: Current Perspectives.

Authors:  Emanuele Valeriani; Nicoletta Riva; Marcello Di Nisio; Walter Ageno
Journal:  Vasc Health Risk Manag       Date:  2019-10-22
View more
  1 in total

1.  Contemporary management of acute and chronic mesenteric ischemia: 10-year experience from a multihospital healthcare system.

Authors:  Elizabeth A Andraska; Lillian M Tran; Lindsey M Haga; Allison K Mak; Michael C Madigan; Michel S Makaroun; Mohammad H Eslami; Rabih A Chaer
Journal:  J Vasc Surg       Date:  2021-11-14       Impact factor: 4.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.